For the year ending 2025-12-31, PLX made $52,744K in revenue. -$6,604K in net income. Net profit margin of -12.52%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 52,744 | |||
| Cost of goods sold | 26,993 | |||
| Research and development expenses | 19,569 | |||
| Selling, general and administrative expenses | 11,682 | |||
| Operating income (loss) | -5,500 | |||
| Financial expenses | 1,191 | |||
| Financial income | 1,083 | |||
| Financial income (expenses), net | -108 | |||
| Income (loss) before taxes on income | -5,608 | |||
| Taxes on income | 996 | |||
| Net income (loss) | -6,604 | |||
| Basic EPS | -0.08 | |||
| Diluted EPS | -0.08 | |||
| Basic Average Shares | 78,546,234 | |||
| Diluted Average Shares | 78,546,234 | |||
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)